HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Myocardial Infarction Alters Adaptation of the Tethered Mitral Valve.

AbstractBACKGROUND:
In patients with myocardial infarction (MI), leaflet tethering by displaced papillary muscles induces mitral regurgitation (MR), which doubles mortality. Mitral valves (MVs) are larger in such patients but fibrosis sets in counterproductively. The investigators previously reported that experimental tethering alone increases mitral valve area in association with endothelial-to-mesenchymal transition.
OBJECTIVES:
The aim of this study was to explore the clinically relevant situation of tethering and MI, testing the hypothesis that ischemic milieu modifies mitral valve adaptation.
METHODS:
Twenty-three adult sheep were examined. Under cardiopulmonary bypass, the papillary muscle tips in 6 sheep were retracted apically to replicate tethering, short of producing MR (tethered alone). Papillary muscle retraction was combined with apical MI created by coronary ligation in another 6 sheep (tethered plus MI), and left ventricular remodeling was limited by external constraint in 5 additional sheep (left ventricular constraint). Six sham-operated sheep were control subjects. Diastolic mitral valve surface area was quantified by 3-dimensional echocardiography at baseline and after 58 ± 5 days, followed by histopathology and flow cytometry of excised leaflets.
RESULTS:
Tethered plus MI leaflets were markedly thicker than tethered-alone valves and sham control subjects. Leaflet area also increased significantly. Endothelial-to-mesenchymal transition, detected as α-smooth muscle actin-positive endothelial cells, significantly exceeded that in tethered-alone and control valves. Transforming growth factor-β, matrix metalloproteinase expression, and cellular proliferation were markedly increased. Uniquely, tethering plus MI showed endothelial activation with vascular adhesion molecule expression, neovascularization, and cells positive for CD45, considered a hematopoietic cell marker. Tethered plus MI findings were comparable with external ventricular constraint.
CONCLUSIONS:
MI altered leaflet adaptation, including a profibrotic increase in valvular cell activation, CD45-positive cells, and matrix turnover. Understanding cellular and molecular mechanisms underlying leaflet adaptation and fibrosis could yield new therapeutic opportunities for reducing ischemic MR.
AuthorsJacob P Dal-Bianco, Elena Aikawa, Joyce Bischoff, J Luis Guerrero, Jesper Hjortnaes, Jonathan Beaudoin, Catherine Szymanski, Philipp E Bartko, Margo M Seybolt, Mark D Handschumacher, Suzanne Sullivan, Michael L Garcia, Adam Mauskapf, James S Titus, Jill Wylie-Sears, Whitney S Irvin, Miguel Chaput, Emmanuel Messas, Albert A Hagège, Alain Carpentier, Robert A Levine, Leducq Transatlantic Mitral Network
JournalJournal of the American College of Cardiology (J Am Coll Cardiol) Vol. 67 Issue 3 Pg. 275-87 (Jan 26 2016) ISSN: 1558-3597 [Electronic] United States
PMID26796392 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Transforming Growth Factor beta
  • Matrix Metalloproteinases
Topics
  • Adaptation, Physiological
  • Animals
  • Cell Proliferation (physiology)
  • Disease Models, Animal
  • Echocardiography, Three-Dimensional (methods)
  • Epithelial-Mesenchymal Transition (physiology)
  • Matrix Metalloproteinases (metabolism)
  • Mitral Valve (diagnostic imaging, physiopathology)
  • Mitral Valve Insufficiency (etiology, metabolism, pathology, physiopathology)
  • Myocardial Infarction (complications, metabolism, pathology)
  • Papillary Muscles (pathology)
  • Sheep
  • Transforming Growth Factor beta (metabolism)
  • Ventricular Remodeling (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: